COMPANY

vTv Therapeutics

HQ: High Point, NC source · vtvtherapeutics.com ↗

Keywords: metabolic diabetes mellitus Alzheimer's Disease Type 2 Diabetes Mellitus Type 1 Diabetes Mellitus Type 1 Diabetes (T1D) Alzheimer Disease Obesity Coagulation Venous Thromboembolism Embolism and Thrombosis Hip Fractures GK1-399 (formerly TTP399) TTP399 Azeliragon TTP889 Cadisegliatin TTP054 TTP273 TTP4000 TTP435

Location: High Point, NC · source · Oct 15, 2026

Profile checked Oct 10, 2026

$80.0MRaised (2 yrs)14Trials (company is sponsor)

Timeline

2026-10 Trial start Phase 2: Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems source ↗
Sep 2, 2025 Raise Private placement: $80M (total, as published), announced Sep 2, 2025. Source: company release on GlobeNewswire. source ↗
Jun 14, 2024 Trial start Phase 3: Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes source ↗
Jun 27, 2019 Trial start Phase 2: Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance source ↗
Oct 25, 2017 Trial start Phase 1/Phase 2: Evaluation of TTP399 in Patients With Type 1 Diabetes source ↗
2016-12 Trial start Phase 3: 2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension) source ↗
2015-12 Trial start Phase 2: A Study to Evaluate Safety and Efficacy of TTP273 for 12 Weeks in Subjects With Type 2 Diabetes source ↗
2015-04 Trial start Phase 3: Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease source ↗
2015-03 Trial start Phase 2: Add Glucokinase Activator to Target A1c source ↗
2012-08 Trial start Phase 2: A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes source ↗
2011-11 Trial start Phase 1/Phase 2: A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes source ↗
2011-10 Trial start Phase 1: A Safety Study of TTP4000 in Subjects With Alzheimer's Disease source ↗
2009-06 Trial start Phase 2: Left Ventricular Assist Device (LVAD) Specialized Centers of Clinically Orientated Research (SCCOR) Coagulation - Acute Intrinsic Pathway Antagonist (IPA) source ↗
2009-02 Trial start Phase 2: Safety Study of the Inhibition of Agouti-related Protein (AgRP) for the Management of Obesity and Weight Loss source ↗
2005-01 Trial start Phase 2: Factor IX Inhibition in Thrombosis Prevention (The FIXIT Trial) source ↗

Upcoming milestones

2027-04 (ESTIMATED) · Phase 3 · Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes · NCT06334133
2027-06 (ESTIMATED) · Phase 2 · Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems · NCT07616206

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $80.0M. Last 2 years.

Sep 2, 2025 Private placement: $80M (total, as published), announced Sep 2, 2025. Source: company release on GlobeNewswire. source ↗

Clinical trials (lead sponsor) 14

Record	Title	Phase	Status	Start	Primary completion
NCT07616206	Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems	Phase 2	Not yet recruiting	2026-10	2027-06 (estimated)
NCT06334133	Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes	Phase 3	Active, not recruiting	Jun 14, 2024	2027-04 (estimated)
NCT03335371	Evaluation of TTP399 in Patients With Type 1 Diabetes	Phase 1/Phase 2	Completed	Oct 25, 2017	Dec 20, 2019 (actual)
NCT03980730	Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance	Phase 2	Terminated	Jun 27, 2019	Dec 1, 2020 (actual)
NCT02916056	2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)	Phase 3	Terminated	2016-12	Jun 1, 2018 (actual)
NCT02080364	Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease	Phase 3	Terminated	2015-04	Jun 1, 2018 (actual)
NCT01665352	A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes	Phase 2	Completed	2012-08	2013-05 (actual)
NCT02653599	A Study to Evaluate Safety and Efficacy of TTP273 for 12 Weeks in Subjects With Type 2 Diabetes	Phase 2	Completed	2015-12	2016-11 (actual)
NCT02405260	Add Glucokinase Activator to Target A1c	Phase 2	Completed	2015-03	2016-07 (actual)
NCT01548430	A Safety Study of TTP4000 in Subjects With Alzheimer's Disease	Phase 1	Completed	2011-10	2013-02 (actual)
NCT01474083	A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes	Phase 1/Phase 2	Completed	2011-11	2012-08 (actual)
NCT00779519	Safety Study of the Inhibition of Agouti-related Protein (AgRP) for the Management of Obesity and Weight Loss	Phase 2	Completed	2009-02	2009-12 (actual)
NCT00909298	Left Ventricular Assist Device (LVAD) Specialized Centers of Clinically Orientated Research (SCCOR) Coagulation - Acute Intrinsic Pathway Antagonist (IPA)	Phase 2	Terminated	2009-06	2010-06 (actual)
NCT00119457	Factor IX Inhibition in Thrombosis Prevention (The FIXIT Trial)	Phase 2	Completed	2005-01	Not listed